Cynosure Beats Up on Analysts Yet Again

Cynosure (Nasdaq: CYNO  ) reported earnings on Feb. 14. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Cynosure beat expectations on revenue and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly, and GAAP earnings per share expanded.

Margins increased across the board.

Revenue details
Cynosure recorded revenue of $34.1 million. The four analysts polled by S&P Capital IQ hoped for sales of $33.3 million on the same basis. GAAP reported sales were 53% higher than the prior-year quarter's $22.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.08. The four earnings estimates compiled by S&P Capital IQ predicted $0.05 per share. GAAP EPS were $0.08 for Q4 versus -$0.07 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 56.3%, 40 basis points better than the prior-year quarter. Operating margin was 4.2%, 700 basis points better than the prior-year quarter. Net margin was 3.2%, 680 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $30.5 million. On the bottom line, the average EPS estimate is -$0.04.

Next year's average estimate for revenue is $135.5 million. The average EPS estimate is $0.17.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 369 members rating the stock outperform and 10 members rating it underperform. Among 107 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 105 give Cynosure a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is outperform, with an average price target of $17.50.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Cynosure performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.

• Add Cynosure to My Watchlist.